6月16日,先声药业集团旗下的抗肿瘤创新药公司先声再明宣布与NextCure建立战略合作伙伴关系,共同开发针对CDH6靶点的新型抗体药物偶联物(ADC)新药SIM0505,用于治疗实体瘤。此次合作还包括授权NextCure使用先声再明ADC技术平台专有的连接子和TOPOi有效载荷,用于NextCure一款临床前阶段新型靶点ADC的开发。先声再明将拥有这款新型靶点ADC在大中华区的权利。根据协议,...
Source Link6月16日,先声药业集团旗下的抗肿瘤创新药公司先声再明宣布与NextCure建立战略合作伙伴关系,共同开发针对CDH6靶点的新型抗体药物偶联物(ADC)新药SIM0505,用于治疗实体瘤。此次合作还包括授权NextCure使用先声再明ADC技术平台专有的连接子和TOPOi有效载荷,用于NextCure一款临床前阶段新型靶点ADC的开发。先声再明将拥有这款新型靶点ADC在大中华区的权利。根据协议,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.